摩熵化学
数据库官网
小程序
打开微信扫一扫
首页 分子通 化学资讯 化学百科 反应查询 关于我们
请输入关键词

(2R,3R,5R,6R)-3,5-Bis-benzyloxy-2-ethylsulfanyl-6-methyl-tetrahydro-pyran | 172361-29-4

中文名称
——
中文别名
——
英文名称
(2R,3R,5R,6R)-3,5-Bis-benzyloxy-2-ethylsulfanyl-6-methyl-tetrahydro-pyran
英文别名
(2R,3R,5R,6R)-2-ethylsulfanyl-6-methyl-3,5-bis(phenylmethoxy)oxane
(2R,3R,5R,6R)-3,5-Bis-benzyloxy-2-ethylsulfanyl-6-methyl-tetrahydro-pyran化学式
CAS
172361-29-4
化学式
C22H28O3S
mdl
——
分子量
372.529
InChiKey
KDUIDBBRSAMDHF-BRKWEVRTSA-N
BEILSTEIN
——
EINECS
——
  • 物化性质
  • 计算性质
  • ADMET
  • 安全信息
  • SDS
  • 制备方法与用途
  • 上下游信息
  • 反应信息
  • 文献信息
  • 表征谱图
  • 同类化合物
  • 相关功能分类
  • 相关结构分类

计算性质

  • 辛醇/水分配系数(LogP):
    4.6
  • 重原子数:
    26
  • 可旋转键数:
    8
  • 环数:
    3.0
  • sp3杂化的碳原子比例:
    0.45
  • 拓扑面积:
    53
  • 氢给体数:
    0
  • 氢受体数:
    4

反应信息

  • 作为反应物:
    描述:
    (2R,3R,5R,6R)-3,5-Bis-benzyloxy-2-ethylsulfanyl-6-methyl-tetrahydro-pyran 在 palladium on activated charcoal N-碘代丁二酰亚胺氢气silver trifluoromethanesulfonate 作用下, 以 二氯甲烷溶剂黄146甲苯 为溶剂, 反应 0.83h, 生成 (1S,3R,4R,5S,6R,7R,20R,22S,23S,24R)-23-((2R,3R,5R,6R)-3,5-Dihydroxy-6-methyl-tetrahydro-pyran-2-yloxy)-22-methoxy-2,9,18,21,25-pentaoxa-tricyclo[18.2.2.13,7]pentacosane-4,5,6,24-tetraol
    参考文献:
    名称:
    拴系三糖的合成,以探讨糖-蛋白相互作用中糖间的柔性。
    摘要:
    三糖表位的两个晶体结构alpha-D-Galp(1-> 2)[alpha-D-Abep(1-> 3)alpha-D-Manp1-> OCH(3)1与抗体Fab和单链Fv片段已用于指导分子内束缚的设计,该束缚将三糖配体约束为接近结合态的构象。配体的预组织应克服对结合的熵罚并提供增强的亲和力。使用三个系链[O(CH(2))(n)()O,n = 6、7和8]固定甘露糖和半乳糖残基的溶剂暴露C6原子。使用了两种合成方案。第一种使用带有被保护为三苯甲基醚6-8的系链的1-硫代半乳糖苷乙基。供体6-8中的任何一个在C6处含有甲磺酸盐的甘露吡喃糖苷5的糖基化得到二糖37-39。随后除去三苯甲基,允许在系链的ω-羟基上生成醇盐,以38%的收率置换磺酸盐。通过比较,当掺入ω-甲磺酰氧基系绳作为甘露糖苷9时,与半乳糖基供体10反应后的二糖产物52以61%的产率转化为大环4。通过硫代糖苷化学法引入3,6-二脱氧
    DOI:
    10.1021/jo9806097
  • 作为产物:
    描述:
    溴甲苯 、 Ethyl 3,6-dideoxy-1-thio-D-xylo-hexopyranoside 在 sodium hydride 作用下, 以 N,N-二甲基甲酰胺 为溶剂, 生成 Ethyl 2,4-di-O-benzyl-3,6-dideoxy-1-thio-β-D-xylo-hexopyranoside 、 (2R,3R,5R,6R)-3,5-Bis-benzyloxy-2-ethylsulfanyl-6-methyl-tetrahydro-pyran
    参考文献:
    名称:
    Synthesis of a Pentasaccharide Epitope for the Investigation of Carbohydrate-Protein Interactions
    摘要:
    Pyranose residues of a polysaccharide that are not involved in the principal sugar-protein antibody combining site, filled by trisaccharide 1, cause a 50-fold reduction in intrinsic affinity. The antibody is crystallographically characterized, and the residue responsible for the lost binding energy has been identified as the terminal disaccharide Rha-->Gal of pentasaccharide 5. This disaccharide segment of 5 may avoid protein contact by adopting the ''anti'' conformer about the preceding Man-Rha glycosidic linkage. Monosaccharide thioglycoside synthons 6-9 were used in NIS-promoted glycosylations to synthesize the pentasaccharide as a glycoside that was suitable for binding and solution conformational studies. Disaccharide 29 was obtained upon the addition of rhamnose building unit 6 to the (trimethylsilyl)ethyl galactopyranoside 10 followed by protecting group manipulation. The sequential addition of 7-9 to 29 afforded the pentasaccharide derivative 35 bearing a 2-O-benzoate group suited for subsequent 1,2-trans-glycoside synthesis following its conversion to a glycosyl imidate. In order to preserve the integrity of the 3,6-dideoxyhexopyranosyl glycosidic bond during cleavage of the (trimethylsilyl)ethyl group leading to the imidate 39, it was essential to convert the benzylated pentasaccharide target 35 into its fully acylated derivative 37. Pentasaccharide 5 was obtained by transesterification of the protected glycoside 40 formed via 39. Qualitative NOE measurements suggest a predominant solution conformation for 5 that cannot be adopted in the bound state due to protein-oligosaccharide clashes at the periphery of the binding site.
    DOI:
    10.1021/jo00127a043
点击查看最新优质反应信息

同类化合物

(βS)-β-氨基-4-(4-羟基苯氧基)-3,5-二碘苯甲丙醇 (S,S)-邻甲苯基-DIPAMP (S)-(-)-7'-〔4(S)-(苄基)恶唑-2-基]-7-二(3,5-二-叔丁基苯基)膦基-2,2',3,3'-四氢-1,1-螺二氢茚 (S)-盐酸沙丁胺醇 (S)-3-(叔丁基)-4-(2,6-二甲氧基苯基)-2,3-二氢苯并[d][1,3]氧磷杂环戊二烯 (S)-2,2'-双[双(3,5-三氟甲基苯基)膦基]-4,4',6,6'-四甲氧基联苯 (S)-1-[3,5-双(三氟甲基)苯基]-3-[1-(二甲基氨基)-3-甲基丁烷-2-基]硫脲 (R)富马酸托特罗定 (R)-(-)-盐酸尼古地平 (R)-(-)-4,12-双(二苯基膦基)[2.2]对环芳烷(1,5环辛二烯)铑(I)四氟硼酸盐 (R)-(+)-7-双(3,5-二叔丁基苯基)膦基7''-[((6-甲基吡啶-2-基甲基)氨基]-2,2'',3,3''-四氢-1,1''-螺双茚满 (R)-(+)-7-双(3,5-二叔丁基苯基)膦基7''-[(4-叔丁基吡啶-2-基甲基)氨基]-2,2'',3,3''-四氢-1,1''-螺双茚满 (R)-(+)-7-双(3,5-二叔丁基苯基)膦基7''-[(3-甲基吡啶-2-基甲基)氨基]-2,2'',3,3''-四氢-1,1''-螺双茚满 (R)-(+)-4,7-双(3,5-二-叔丁基苯基)膦基-7“-[(吡啶-2-基甲基)氨基]-2,2”,3,3'-四氢1,1'-螺二茚满 (R)-3-(叔丁基)-4-(2,6-二苯氧基苯基)-2,3-二氢苯并[d][1,3]氧杂磷杂环戊烯 (R)-2-[((二苯基膦基)甲基]吡咯烷 (R)-1-[3,5-双(三氟甲基)苯基]-3-[1-(二甲基氨基)-3-甲基丁烷-2-基]硫脲 (N-(4-甲氧基苯基)-N-甲基-3-(1-哌啶基)丙-2-烯酰胺) (5-溴-2-羟基苯基)-4-氯苯甲酮 (5-溴-2-氯苯基)(4-羟基苯基)甲酮 (5-氧代-3-苯基-2,5-二氢-1,2,3,4-oxatriazol-3-鎓) (4S,5R)-4-甲基-5-苯基-1,2,3-氧代噻唑烷-2,2-二氧化物-3-羧酸叔丁酯 (4S,4''S)-2,2''-亚环戊基双[4,5-二氢-4-(苯甲基)恶唑] (4-溴苯基)-[2-氟-4-[6-[甲基(丙-2-烯基)氨基]己氧基]苯基]甲酮 (4-丁氧基苯甲基)三苯基溴化磷 (3aR,8aR)-(-)-4,4,8,8-四(3,5-二甲基苯基)四氢-2,2-二甲基-6-苯基-1,3-二氧戊环[4,5-e]二恶唑磷 (3aR,6aS)-5-氧代六氢环戊基[c]吡咯-2(1H)-羧酸酯 (2Z)-3-[[(4-氯苯基)氨基]-2-氰基丙烯酸乙酯 (2S,3S,5S)-5-(叔丁氧基甲酰氨基)-2-(N-5-噻唑基-甲氧羰基)氨基-1,6-二苯基-3-羟基己烷 (2S,2''S,3S,3''S)-3,3''-二叔丁基-4,4''-双(2,6-二甲氧基苯基)-2,2'',3,3''-四氢-2,2''-联苯并[d][1,3]氧杂磷杂戊环 (2S)-(-)-2-{[[[[3,5-双(氟代甲基)苯基]氨基]硫代甲基]氨基}-N-(二苯基甲基)-N,3,3-三甲基丁酰胺 (2S)-2-[[[[[((1S,2S)-2-氨基环己基]氨基]硫代甲基]氨基]-N-(二苯甲基)-N,3,3-三甲基丁酰胺 (2S)-2-[[[[[[((1R,2R)-2-氨基环己基]氨基]硫代甲基]氨基]-N-(二苯甲基)-N,3,3-三甲基丁酰胺 (2-硝基苯基)磷酸三酰胺 (2,6-二氯苯基)乙酰氯 (2,3-二甲氧基-5-甲基苯基)硼酸 (1S,2S,3S,5S)-5-叠氮基-3-(苯基甲氧基)-2-[(苯基甲氧基)甲基]环戊醇 (1S,2S,3R,5R)-2-(苄氧基)甲基-6-氧杂双环[3.1.0]己-3-醇 (1-(4-氟苯基)环丙基)甲胺盐酸盐 (1-(3-溴苯基)环丁基)甲胺盐酸盐 (1-(2-氯苯基)环丁基)甲胺盐酸盐 (1-(2-氟苯基)环丙基)甲胺盐酸盐 (1-(2,6-二氟苯基)环丙基)甲胺盐酸盐 (-)-去甲基西布曲明 龙蒿油 龙胆酸钠 龙胆酸叔丁酯 龙胆酸 龙胆紫-d6 龙胆紫